All samples analyzed from the 30 mg dose group in the NEX-22 Phase I study
Nanexa announced today that all pharmacokinetic (PK) samples from the final dose group, 30 mg of the Phase I study for NEX-22, now have been analyzed. The results show increased exposure in line with the dose escalation and further demonstrate a controlled and prolonged release of liraglutide, which supports a one-month depot of liraglutide.
“The full results of the NEX-22 study will be presented at scientific congresses, with participation at the ADA (American Diabetes Association) in June being one of the highlights,” says David Westberg, CEO of Nanexa. “The results also strengthen our position in our discussions with potential partners for the NEX-22 project.”
